LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates
- 15 July 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (14), 4059-4072
- https://doi.org/10.1158/0008-5472.CAN-18-0327
Abstract
Progress in understanding tumor stromal biology has been constrained in part because cancer-associated fibroblasts (CAF) are a heterogeneous population with limited cell-type-specific protein markers. Using RNA expression profiling, we identified the membrane protein leucine-rich repeat containing 15 (LRRC15) as highly expressed inmultiple solid tumor indications with limited normal tissue expression. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGF beta on activated fibroblasts (aSMA thorn) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymalmarker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies. ABBV-085's unique mechanism of action relied upon the cell-permeable properties of MMAE to preferentially kill cancer cells over LRRC15-positive CAF while also increasing immune infiltrate (e.g., F4/80(+) thorn macrophages) in the tumor microenvironment. In summary, these findings validate LRRC15 as a novel therapeutic target in multiple solid tumor indications and support the ongoing clinical development of the LRRC15-targeted ADC ABBV-085. Significance: These findings identify LRRC15 as a new marker of cancer-associated fibroblasts and cancers of mesenchymal origin and provide preclinical evidence for the efficacy of an antibody-drug conjugate targeting the tumor stroma. (C) 2018 AACR.Other Versions
This publication has 43 references indexed in Scilit:
- Induced Pluripotent Stem Cells from Human Hair Follicle Mesenchymal Stem CellsStem Cell Reviews and Reports, 2012
- The Pancreas Cancer MicroenvironmentClinical Cancer Research, 2012
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Concise Review: Role of Mesenchymal Stem Cells in Wound RepairStem Cells Translational Medicine, 2012
- Fibrocytes: emerging effector cells in chronic inflammationNature Reviews Immunology, 2011
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic CancerScience, 2009
- Progression-Specific Genes Identified by Expression Profiling of Matched Ductal Carcinomas In situ and Invasive Breast Tumors, Combining Laser Capture Microdissection and Oligonucleotide Microarray AnalysisCancer Research, 2006
- Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachmentProtein Engineering, Design and Selection, 2006
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Tumors: Wounds That Do Not HealThe New England Journal of Medicine, 1986